Novo Nordisk shares fell as much as 6% on Monday after the Danish drugmaker’s ambitious growth targets aimed at reviving its fortunes in the increasingly competitive obesity drug market failed to impress investors. Copenhagen-listed shares were down 6% by late morning, while Novo’s US-listed shares also slipped over 6% in…
The S&P 500 Index rose to 7,650 points on Monday as top technology stocks continued rising. It has jumped…
BitMine stock has held steady above a crucial support level as the company nears an inflection point in its…
Accenture (ACN) stock fell 4% on Friday after Guggenheim downgraded the consulting and technology services company to Neutral from…
Micron Technology (MU) shares rose on Friday as RBC Capital Markets said the memory-chip maker’s valuation does not fully…
Saudi Aramco has told at least two European refining customers they will receive no crude oil in October following…
US stocks ended mixed on Friday as investors wrapped up a volatile week marked by the Federal Reserve’s first…
SpaceX stock has moved sideways at an important price, even after the company received a $964 million deal by…
India’s decision to introduce a merchant discount rate on selected UPI payments has reopened a debate over who should…
The KOSPI edged higher on Wednesday as gains in Samsung Electronics and SK Hynix helped South Korean shares stabilise…
